We provide you with 20 years of free, institutional-grade data for ALT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALT. Explore the full financial landscape of ALT stock.
| Reported Date | CIK | Ticker | Type |
|---|
Altimmune, Inc(NASDAQ:ALT) 
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID...
Website: http://www.altimmune.com
Founded: 1997
Full Time Employees: 25
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ALT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.